In last trading session, KalVista Pharmaceuticals Inc (NASDAQ:KALV) saw 0.28 million shares changing hands with its beta currently measuring 0.88. Company’s recent per share price level of $11.41 trading at $0.23 or 2.06% at ring of the bell on the day assigns it a market valuation of $555.84M. That closing price of KALV’s stock is at a discount of -47.94% from its 52-week high price of $16.88 and is indicating a premium of 36.81% from its 52-week low price of $7.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.32 million shares which gives us an average trading volume of 352.64K if we extend that period to 3-months.
For KalVista Pharmaceuticals Inc (KALV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.91 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
KalVista Pharmaceuticals Inc (NASDAQ:KALV) trade information
Upright in the green during last session for gaining 2.06%, in the last five days KALV remained trading in the green while hitting it’s week-highest on Monday, 11/04/24 when the stock touched $11.41 price level, adding 11.21% to its value on the day. KalVista Pharmaceuticals Inc’s shares saw a change of -6.86% in year-to-date performance and have moved 7.54% in past 5-day. KalVista Pharmaceuticals Inc (NASDAQ:KALV) showed a performance of 3.82% in past 30-days. Number of shares sold short was 6.81 million shares which calculate 13.35 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 42.95% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -75.28% in reaching the projected high whereas dropping to the targeted low would mean a loss of -75.28% for stock’s current value.
KalVista Pharmaceuticals Inc (KALV) estimates and forecasts
Statistics highlight that KalVista Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -5.55% of value to its shares in past 6 months, showing an annual growth rate of 21.51% while that of industry is 18.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
And 5 analysts are in estimates of company making revenue of 22.37M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.06% during past 5 years.
KalVista Pharmaceuticals Inc (NASDAQ:KALV)’s Major holders
Insiders are in possession of 1.27% of company’s total shares while institution are holding 106.75 percent of that, with stock having share float percentage of 108.12%. Investors also watch the number of corporate investors in a company very closely, which is 106.75% institutions for KalVista Pharmaceuticals Inc that are currently holding shares of the company. VR ADVISER, LLC is the top institutional holder at KALV for having 6.25 million shares of worth $73.62 million. And as of 2024-06-30, it was holding 14.3373 of the company’s outstanding shares.
The second largest institutional holder is TANG CAPITAL MANAGEMENT LLC, which was holding about 4.22 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6783 of outstanding shares, having a total worth of $49.7 million.
